Recombinant CD3E (Otelixizumab Biosimilar) antibody

Catalog No. ABIN7538054

This Humanized Chimeric antibody specifically detects CD3E (Otelixizumab Biosimilar) in ELISA and WB. It exhibits reactivity toward Human.

Quick Overview for Recombinant CD3E (Otelixizumab Biosimilar) antibody (ABIN7538054)

Target: CD3E (Otelixizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Humanized

Clonality: Chimeric

Conjugate: This CD3E (Otelixizumab Biosimilar) antibody is un-conjugated

Application: ELISA, Western Blotting (WB)

Grade: Research Grade

Product Details anti-CD3E (Otelixizumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Otelixizumab Biosimilar - Anti-CD3E mAb - Research Grade

Characteristics: Antibody Type: IgG1-lambda

Purification: Recombinant antibody expressed in mammalien cells and purified.

Purity: > 85%

Isotype: IgG1 lambda

Application Details

Restrictions: For Research Use only

Handling

Buffer: PBS buffer PH7.5

Storage: -80 °C

Storage Comment: store at -80°C

Target Details for CD3E (Otelixizumab Biosimilar)

Target: CD3E (Otelixizumab Biosimilar)

Target Type: Biosimilar

Background: Otelixizumab is a recombinant Humanized (from rat) antibody to Human CD3E. Otelixizumab, also known as TRX4, is a monoclonal antibody, which is being developed for the treatment of type 1 diabetes and other autoimmune diseases.

CAS-No: 881191-44-2